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Involvement of organ systems of lupus includes 
musculoskeletal, hematologic, mucocutaneus, 
neurologic, cardiopulmonary, renal, and ocular 
organ systems. One of the most significant 
manifestation is neurologic symptoms, with or 
without psychiatric symptoms, widely known as 
Neuropsychiatric Systemic Lupus Erythematosus 
(NPSLE).1,5 According to American College of 
Rheumatology, NPLSE was classified based on 
central and peripheral nervous manifestation onto 
19 case definitions.5 NPSLE is found on 12.2%-
94.7% patients prior to the diagnosis, during the 
diagnosis, following the diagnosis, or even during 
undetected or quiescent period of disease.4
NPSLE is quite burdensome in terms of quality of 
life, psychological comorbidity, and even mortality. 
Lower life quality were found in SLE patients 
who have NPSLE, includes any neurological, 
psychological-emotional, or cognitive dysfunction, 
rather than SLE patients without NPSLE. Besides 
life quality, the presence of psychological 
disturbance. like depression or anxiety, were higher 
among NPSLE patients.6 Mortality rate was also 
worrisome, as NPSLE patients may have 10-fold 
higher mortality rate than other SLE patients.7 
Further, NPSLE patients also have higher risk of 
having neurologic complications in the future.8
Despite the alarming burden of NPSLE, 
diagnosing NPSLE among SLE patients is quite 
challenging for physician. Such diagnosis should 
be made by the combination of immunology, 
neurology, and psychiatric examination.8,9 
Fortunately, despite the complex assesment and 
burden of NPSLE, an adequate treatment can 
prevent the progression of disease.8,10 Therefore, it 
is important to encourage physicians in recognizing 
NPSLE in daily clinical practice.6–10
In Indonesia, especially in Department of 
Internal Medicine, Hasan Sadikin General Hospital, 
data regarding the distribution of neuropsychiatric 
manifestation among SLE patients had not been 
available yet. Such data were needed for physicians 
to increase the awareness of NPSLE and to be 
able to treat them adequately. NPSLE screening 
Abstract
Background: Systemic Lupus Erythematosus (SLE) 
is an autoimmune diseases caused by deposition of 
immune complex with the involvement of various organ 
system and certain autoantibodies production. One of 
the most significant manifestation is neuropsychiatric 
symptoms, known as NPSLE (Neuropsychiatric Systemic 
Lupus Erythematosus). This study aims to portray the 
distribution of neuropsychiatric manifestation of SLE 
patients using a screening method in Hasan Sadikin 
General Hospital. 
Method: An observative, descriptive categoric study, 
with consecutive sampling were done. Data were 
collected by spreading the questionnaire to subjects 
diagnosed as SLE who visiting Hasan Sadikin General 
Hospital during August-October 2016 and by tracing 
their medical records. Data analyzed included age, sex, 
education background, duration of lupus, diagnosis 
criteria, ongoing therapy, and neuropsychiatric 
manifestation. 
Result: Samples volunteered in this study were 97 
patients. Of them 94 patients (96.9%) were women and 
47 patients (48.5%) were senior high school graduated. 
Most common diagnosis criteria found was positive 
ANA test (91.8%). Most necessary ongoing therapy 
given was methylprednisolone (96.9%). Common 
neuropsychiatric manifestations were mood disorders 
(73,2%), headache (57,7%), and mononeuropathy 
(51,5%).
Conclusion: The common psychiatric, central nervous, 
and peripheral nervous manifestations were mood 
disorder, headache, and mononeuropathy, respectively. 
Keywords: Neuropsychiatry, NPSLE Screening, 
Systhemic Lupus Erythematosus.
Introduction
Systemic Lupus Erythematosus (SLE) or widely 
known as lupus, is an autoimmune diseases 
caused by deposition of immune complex with 
involvement of various organ systems and specific 
autoantibodies production.1,2 In Asia, prevalence 
of lupus was estimated around 50 to 100 cases per 
100.000 population.3 Female patients has accounted 
for 76.4%-95.4% of all recorded SLE patients.4
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could be done using a questionnaire, even though it is not 
recommended to be used as the sole diagnosis.11 This study 
aims to portray the distribution of NPSLE manifestation using 
a NPSLE screening quistionnaire.
Method
Study was conducted at Rheumatology clinic in dr. Hasan 
Sadikin General Hospital, by using categoric descriptive study 
design. Subject of the study were all SLE patients visited 
Hasan Sadikin General Hospital during August to October 
2016. Inclusion criteria were: all SLE patients recorded in 
medical record of Dr. Hasan Sadikin General Hospital, and 
routinely underwent follow-up during the period of the study. 
Patients with incomplete medical record data, lacking desired 
criteria, and unwilling to be involved in this study would 
be excluded. Minimum samples needed were 97 samples. 
Samples were selected by consecutive sampling method, 
which data collected until the minimum sample obtained.
NPSLE manifestation was screened by questionnaire. 
Questionnaire used was Mosca and colleague 38-questions 
2011 questionnaire, and Kundu and colleague 2012 peripheral 
nervous sign of SLE.11,12 Questionnaire was translated with 
double translate method (English-Bahasa Indonesia-English) 
by certified translator, validated by Cronbach’s Alpha of 0.802 
and Pearson correlation value of 0.913 and 0.916, respectively. 
Questionnaire was then consulted with Department of 
Neurology, Dr. Hasan Sadikin General Hospital. The 
questionnaires were filled by patients with supervision to 
minimize the bias. Questionnaire filling was done in workdays 
within time period of study until minimum sample obtained.
Secondary data were obtained from medical records, 
included age, sex, education background, duration of diseases, 
diagnosis criteria, and ongoing therapy. The collected data 
were sorted by variables and analyzed.
Ethical clearance were approved prior to data collection. 
Analysis were conducted in descriptive manner by counting 
number and percentage by using Microsoft Office Excel. 
Variables of this study were age, sex, education background, 
duration of lupus, diagnosis criteria, ongoing therapy, and 
neuropsychiatric manifestation. Normality test of numeric 
variables data (age, age during the establishment of diagnosis, 
and duration of disease) was done using Saphiro-Wilk test to 
reveal whether the data is well distributed or not. Data were 
presented as mean “(± Standard Deviation)” if distributed 
well, or presented as “median (range)” if not distributed well.
Results
Within time period of the study, we were able to obtain 
minimum sample of 97 patients. Demographic data of the 
participants of the study were presented in Table 1.
Table 1. Demographic Data
Characteristic (N=97) Results
Age (years) 33 (14-61)*
Women, N(%) 94(96.9)
Age of diagnosis (years) 27 (9-52)*
Duration of Disease (years) 4 (0-20)*
Educational Background, N(%)
Primary School 11(11.3)
Junior High School 20(20.6)
Senior High School 47(48.5)
University 19(19.6)
*: not normally distributed data, presented in median (range)
Duration of SLE were defined as age range since establishment 
of diagnosis until the time of this study conducted. Among 
97 patients, most of participants were women (96.9%) and 
graduated from senior high school (48.5%).
Table 2. Distribution of SLE Patients According to Diagnosis 
Criteria and Ongoing Therapy 
Distribution of patients
N=97
Frequency 
N (%)
Diagnosis Criteria
Malar Rash 64 (66,0%)
Discoid Rash 37 (38,1%)
Photosensitivity 65 (67,0%)
Oral Ulcers 40 (41,2%)
Arthritis 88 (90,7%)
Serositis 23 (23,7%)
Renal Disorder 26 (26,8%)
Neurology Disorder 10 (10,3%)
Hematology Disorder 45 (46,4%)
Immunology Disorder 33 (34,0%)
Positive ANA Test 89 (91,8%)
Ongoing Therapy
Cyclophosphamide 11 (11,3%)
Methylprednisolone 94 (96,9%)
Dexamethasone 1 (1,0%)
Chloroquine 45 (46,4%)
Azatioprin 14 (14,4%)
Methotrexate 5 (5,2%)
Cyclosporin A 1 (1,0%)
Micophenolat Mophetyl 0 (0%)
Distribution of diagnosis criteria met on the first lupus 
diagnosis establishment were presented in Table 2, with 
positive ANA test (91.8%) and arthritis (90.7%) as the most 
common finding.  Table 2 also showed ongoing therapy among 
participants was corticosteroid in form of methylprednisolone 
(96,3%), while the other therapies were less frequent.
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Figure 1. Neuropsychiatric Manifestation Distribution Graphic 
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Figure 1 shows the percentage of each neuropsychiatric manifestation among 
subjects. Headache, cerebrovascular disease, demyleinating syndrome, seizure, chorea, and 
aseptic meningitis are classified as central nervous system manifestation of NPSLE. Acute 
convusional state-cognitive dysfunction, mood disorder, anxiety disorder, and psychosis are 
classified as psychiatry manifestation of NPSLE. Guillain-Barre Syndrome, mononeuropathy, 
polyneuropathy, cranial neuropathy, plexopathy, and myasthenia gravis are classified as 
peripheral nervous system manifestation of NPSLE. The least common NPSLE findings was 
cerebrovascular disease (2.1%), while the most common NPSLE complain is mood disorder
(73.2%).
Discussion
Lupus are likely to be occured in productive-aged women,4 same as our study’s 
results which found 96,9% female participants with median age was 33 (14-61) years old. The
similar finding also showed by the study conducted by Chiewthanakul, et al, which found the 
mean age SLE patients was 35+11.7 years and Kampylafka et al, who found the mean age of
SLE patients was 32+14 years.13,14 Data of current age and age of SLE onset were collected 
due to fact that disease activity and damage were presented more in older age subjects.15 It 
shows that high level of disease activity conveyed by the level of interferon-alpha confirmed 
the conclusion that disease are more common in productive age.16 Median of duration of 
disease in this study was 4 years, with range between 0-20 years. It is similar with founding 
conducted by Kampylafka et al, in which means duration of disease suffered by patients was 
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Figure 1 shows the percentage of each neuropsychiatric 
manifestation among subjects. Headache, cerebrovascular 
disease, demyleinating syndrome, seizur , chorea, and 
aseptic meningitis are classified as central nervous system 
manifestation of NPSLE. Acute convusional state-cognitive 
dysfunction, mood disorder, anxiety disorder, and psychosis 
ar  cla sified  psychiatry manifestation of NPSLE. Guillain-
Barre Syndrome, mononeuropathy, polyneuropathy, cranial 
neuropathy, plexopathy, and myasthenia gravis are classified 
as peripheral nervous system manifestation of NPSLE. The 
least common NPSLE findings was cerebrovascular disease 
(2.1%), while the most common NPSLE complain is mood 
diso der (73.2%). 
Discussion
Lupus are likely to be occured in productive-aged women,4 
same as our study’s results which found 96,9% female 
participants with median a e as 33 (14-61) years ol . 
The similar finding also showed by the study conducted by 
Chiewthanakul, et al, which found the mean age SLE patients 
was 35+11.7 years and Kampylafka et al, who found the mean 
age of SLE patients was 32+14 years.13,14 Data of current age 
and age of SLE onset were collected due to fact that disease 
activity and damage were presented more in older age subjects.15 
It shows that high level of disease activity conveyed by the 
level of interferon-alpha confirmed the conclusion that disease 
are more common in productive age.16 Median of duration of 
disease in this study was 4 years, with range between 0-20 
years. It is similar with founding conducted by Kampylafka et 
al, in which means duration of disease suffered by patients was 
9+7.8 years.13 There are no other NPSLE studies describing 
educational background of subjects. Educational background 
depicted person’s perception of illness and often associated 
with NPSLE, especially cognitive function.17,18
Positive ANA test and arthritis were two most common 
criteria found in this study, while positive ANA test is the most 
common diagnosis criteria with percentage of 96% from all 
participants. The results were similar with Chiewthanakul, et 
al study.13
The use of therapy other than methylprednisolone 
such as cyclophosphamid, azatriopine, chloroquine, and 
methrotexate was rarely found. It was different compared with 
Chiewthanakul, et al study which presented wider variation 
of therapy with proportion of azatriopin, choloroquine, 
metothrexate, cyclophosphamide, and micophenolate mophetil 
were as follow 35%, 62%, 17%, 33%, and 32%.13 It might be 
caused by the subject selection method in our study. We chose 
respondents in outpatient setting who were relatively in stable 
condition. Besides, not all drugs were available in Hasan 
Sadikin General Hospital pharmacy. Current therapy might 
affect direct or inderectly as secondary cause to NPSLE, by 
means of secondary infection caused by suppressed immunity 
or drug adverse effect.8,10
Central nervous system’s manifestations in this study were 
dominated by headache. The finding is similar with the research 
conducted by Al-Shareef, et al which revealed headache in 
34% subjects;19 and the research conducted by Abdel-Nasser, 
et al found headache prevalence was as much as 46.9%.20 
Headache in SLE could be caused by many pathomechanism, 
but some studies suggested that headache-related SLE were 
caused by idiopathic intracranial hypertension.21
Cerebrovascular diseases was the least common finding in 
this study (2.1%). The result was different with the finding 
in  Al-Shareef, et al study, in which found the incidence 
of cerebrovascular in 35% subjects.19 The difference is 
suggested due to the different modalities used in our study. 
The questionnaire can only confirm the preexisting complaint, 
but can not detect the cerebrovascular events as the standard 
examination; while in Al-Shareef, et al study every patients 
was assessed objectively by standard examination in 
hospital.19 Despite the difference, detecting cerebrovascular 
events in SLE patients is important because SLE patients 
reported having 2.05 fold higher chances to be hospitalized 
from cerebrovascular events.22
The finding of aseptic meningitis in our study was quite 
high (37.1%). It is different with the result of study conducted 
by Al-Shareef et al, which only revealed 1.4% cases among 
their study subjects.19 The difference might be happened due 
to over presumptive of aseptic meningitis by the screening 
from questionnaire. The true diagnosis of aseptic meningitis 
is needed to be investigated further. Nevertheless, with a high 
result of aseptic meningitis presumption, physician should be 
aware of aspetic meningitis as to prevent complication such as 
neurological deficit and mortality in the future.23
Questionnaires in this study combined manifestations 
of acute confusional state and cognitive disfunction which 
has never conducted in any other study. Unseparated rate 
from both manifestations was 48.5%. In studies conducted 
by Hanly, et al, Steaup Beekman, et al, and Morrison, et al, 
percentage of acute confusional state were tent to be low 
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(2.6%-6.9%). Cognitive dysfunction was considerably high in 
the study conducted by Steup-Beekman, et al, with percentage 
of 26.5%.24–26 However, mood disorder was neccesary found 
in study conducted by Hanly, et al, with proportion of 16.5% 
from overall samples.26 The findings of mood disorders in this 
study were consistent with the study conducted by Abdel-
Nasser, et al, with proportion of mood disorder as much as 
59.4% of respondents, while we found 73.2% of respondents.20 
Depression, the most common mood disorder in NPSLE, is a 
main concern for clinician treating SLE patients. Depression 
is not only a mere clinical manifestation, but also a serious 
threat to medical adherence, whereas SLE needs a long-term 
therapy.27
In peripheral nervous manifestations, the prevalence 
found were comparatively high compared to central nervous 
manifestation, included Guillan-Barre syndrome, otonomic 
nervous disorder, mononeuropathy, polyneuropathy, and 
plexopathy. The founding is different compared to the study 
perfomed by Hanly, et al and Morrison, et al. They found 
peripheral nervous system manifestation ranging between 
0-24% and 0-7.9%, respectively.26
Distribution of psychiatric disorder among lupus patients 
may vary, due to numerous factor, such as active autoantibodies 
and the method of diagnosis.28 We acknowledged our 
study were tend to be more subjective in making diagnosis 
because we only used questionnaire for assessing NPSLE 
manifestation. Exact diagnosis must be established by 
various supporting modalities, such as electroencephalogram, 
MRI, CT-scan, mental status examination, comprehensive 
nervous system examination, and other psychiatric status 
examination.9,28 Thus, several acquired data were not in line 
with other studies due to the different of interpretation and 
patients’ subjectivity. Questionnaire was only describing 
17 from 19 neuropsychiatric manifestation according to 
American College of Rheumatology (ACR) criteria since this 
questionnaire combined acute confusional state and cognitive 
disorder; and there were no questions to diagnose probable 
myelopathy. Uncompleted patients’ medical record were also 
limiting this study.
Conclusion
The most common psychiatric manifestation was mood 
disorder. The most common CNS manifestation was headache. 
The most common peripheral nervous manifestation was 
mononeuropathy. Neuropsychiatry manifestation screening is 
recommended to be done routinely to all SLE patients. Further 
examination is needed when NPSLE manifestation found 
by the screening, so that optimal therapy could be given to 
the patients. Screening questionnaire used in this study still 
have to be tested to be used as a screening modality to detect 
neuropsychiatric manifestation.
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